Applicability of the International Cooperative Ataxia Rating Scale (ICARS) in younger patients and development of global rating instruments for patients with Ataxia Telangiectasia (AT)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Erydel SPA
- 入组人数
- 80
- 试验地点
- 7
- 主要终点
- Validity & reliability of ICARS in young age group of Ataxia & Ataxia Telangiectasia patients
研究概览
简要总结
Ataxia Telangiectasia (AT) is a severe neurologic disorder with progressive loss of walking capacity, ultimately leading to wheel chair. There is no curative treatment for AT, but some several attempts were made to use different drugs for improving neurologic symptoms. However, all attempts to check the benefit of any drug treatment is hindered by the lack of rating scale that measures the degree of neurologic disease in children with AT. The goal of our study is to validate the ICARS scale, in order to be further used in interventional studies with drugs treatments that might improve neurologic symptoms.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 6.00 Year(s) 至 18.00 Year(s)(—)
- 性别
- All
入选标准
- •1.Patients aged 6-18 years with diagnosed with ataxia, preferably AT will be included.
- •The diagnosis of AT will be made based on the criteria: typical clinical picture plus one of the following:
- •a proven mutation in the ATM gene
- •Deficient ATM protein proven by Western blotting
- •Elevated α-fetoprotein, cerebellar atrophy on MRI and immune deficiency/ chromosomal breakage/ T- cell lymphoreticular malignancy.
- •2.Children aged 6-18 years with suspected AT (fulfilling partially the above criteria will be included) 3.Children aged 6-18 years with AT like disease, with or without proven mutation in the MRE11 gene will be included 4.Children aged 6-18 years of age with ataxia of other known or unknown etiologies might be included, but their total number should not exceed 20% of the cohort in each site.
排除标准
- 未提供
结局指标
主要结局
Validity & reliability of ICARS in young age group of Ataxia & Ataxia Telangiectasia patients
时间窗: None
次要结局
- 1. Total scores comparison in the ages 6-10 and 10-18 years.(2. Correlation of ICARS scores with Clinical Global Impression of Severity (CGI-S) of the disease.)
